Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by emerald03on Apr 25, 2023 12:39pm
274 Views
Post# 35412650

looking at one dollar 2023.

looking at one dollar 2023.All those who predicted one dollar in the past including Biorun will be correct IMO

This clinical trial data is magnificent for a 3 month rrial ,to get so.much efficacy already ,WITH NO TOXICITY,so we can expect longer use over one year to glean even better results with this product ,let alone an enhance upgraded version .
God knows what the potential of an upgraded version  may look like, considering these already outstanding results

Don't  forget Botox is costly, and often has side effects , even with cosmetic use including skin irritation redness ,and weakness of muscles , long term change in facial expression and so on .

I think  one dollar is coming soon, as people start to realize all this ,and 3 to 5 dollars within 2 to 3 years could be possible ie a one billion dollar market cap.
<< Previous
Bullboard Posts
Next >>